Intra Cellular Buy or Sell Recommendation

Macroaxis provides Intra Cellular Therapies Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Intra Cellular positions. The advice algorithm takes into account all of Intra Cellular Therapies Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Intra Cellular buy-and-hold prospective. Please also check Intra Cellular Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon


Risk Tolerance

Execute Advice
Intra Cellular Therapies Inc -- USA Stock  

USD 15.24  0.34  2.28%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Intra Cellular Therapies Inc is 'Strong Hold'.
For the selected time horizon Intra Cellular Therapies Inc has a risk adjusted performance of 0.049, jensen alpha of (0.18), total risk alpha of (1.06), sortino ratio of (0.029607) and treynor ratio of 0.1323
This buy, hold, or sell suggestion tool can be used to cross verify current analyst consensus on Intra Cellular and to analyze the organization potential to grow in the current economic cycle. To make sure Intra Cellular Therapies Inc is not overpriced, please check out all Intra Cellular fundamentals including its Net Income, Earnings Per Share, Current Liabilities, as well as the relationship between Current Ratio and Total Asset . Given that Intra Cellular Thera has Price to Earning of (6.56) times, we strongly advise you confirm Intra Cellular Thera market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Returns Distribution Density

Mean Return0.2Value At Risk2.91
Potential Upside3.26Standard Deviation2.35
 Return Density 

Intra Cellular Greeks

Alpha over DOW
βBeta against DOW=1.46
Overall volatility
 IrInformation ratio =0.03

Intra Cellular Volatility Alert

Intra Cellular Therapies Inc currently demonstrates below average downside deviation of 2.05. It has Information Ratio of -0.03 and Jensen Alpha of -0.18. However, we do advice investors to further question Intra Cellular Therapies Inc expected returns to make sure all indicators are consistent with the current outlook about its relatively low value at risk.
 Better Than Average     
 Worse Than Average Compare Intra Cellular to competition
FundamentalsIntra CellularPeer Average
Return On Equity(26.45) % (15.17) %
Return On Asset(13.99) % (15.64) %
Current Valuation491.09 M152.14 B
Shares Outstanding54.58 M1.43 B
Shares Owned by Insiders12.36 % 6.91 %
Shares Owned by Institutions83.31 % 18.37 %
Number of Shares Shorted5.09 M3.24 M
Price to Earning(6.56) times40.69 times
Price to Book2.03 times14.44 times
Revenue338.68 K9.85 B
Gross Profit330.7 K21.75 B
EBITDA(97.96 M)1.41 B
Net Income(95.05 M)517.71 M
Cash and Equivalents328.12 M3.89 B
Cash per Share6.01 times5.17 times
Debt to Equity0.31 % 0.72 %
Current Ratio28.08 times3.3 times
Book Value Per Share7.36 times13.64 times
Cash Flow from Operations(84.15 M)1.25 B
Short Ratio11.24 times2.09 times
Earnings Per Share(2.19) times2.3 times
Number of Employees3710.67 K
Market Capitalization823.58 M29.78 B
Total Asset542.57 M126.86 B
Retained Earnings(193.05 M)38.24 B
Working Capital401.13 M3.58 B
Current Asset541.82 M36.8 B
Current Liabilities140.69 M33.34 B
Strong Hold


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

   Exercise or conversion by Richard Lerner of 12500 shares of Intra Cellular subject to Rule 16b-3 [view details]
Risk Adjusted Performance0.049
Market Risk Adjusted Performance0.1423
Mean Deviation1.85
Semi Deviation1.9
Downside Deviation2.05
Coefficient Of Variation1158.0
Standard Deviation2.35
Information Ratio(0.025835)
Jensen Alpha(0.18)
Total Risk Alpha(1.06)
Sortino Ratio(0.029607)
Treynor Ratio0.1323
Maximum Drawdown10.14
Value At Risk(2.91)
Potential Upside3.26
Downside Variance4.2
Semi Variance3.63
Expected Short fall(2.47)

Current Valuation

Intra Cellular Current Valuation Analysis
Intra Cellular Therapies Inc is considered the number one company in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 1.17 Billion. Intra Cellular totals roughly 491.09 Million in current valuation claiming about 42% of stocks in Biotechnology industry.